Drug news
NICE does not recommend Remicade, Humira and Simponi as treatments for Ulcerative Colitis - Merck Inc. + Abbvie
The National Institute for Health and Care Excellence (NICE) does not recomend Remicade (infliximab) from Merck Inc. and Simponi from and Humira (adalimumab) from Abbvie to treat moderate to severe forms of Ulcerative Colitis as there is insufficient evidence to show they are clinically and cost effective compared with other therapies currently available. A consultation on the proposed guideline is now open (until October 15).
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.